A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NCT06361927 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: SSGJ-707

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.